Company news

Instil Bio, Inc. news in 2024

Instil Bio, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 12, 2024

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

September 15, 2024

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 12, 2024

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

July 31, 2024

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 20, 2024

Instil Bio Announces Strategic Update

January 15, 2024

Decks in 2024